Multi-omics reveals the DR5-FXR-CHPT1 axis governs hepatocyte pyroptosis via glycerophospholipid remodeling after major partial hepatectomy
简介:
- 作者: Hua Li, Yongsheng tang, XU LU, Xi Luo, Qinghai Lian, Yingqiu Song, Manqiu Kang, Zihan Qiao, Zhihua Rao, Linsen Ye, Zenan Yuan, Changchang JIA
- 杂志: Research Square
- Doi: https://www.doi.org/10.21203/rs.3.rs-9039762/v1
- 出版日期: 2026/3/20
摘要
Background & Aims: Acute liver injury following major partial hepatectomy (PHx), manifesting as small-for-size syndrome (SFSS) and post-hepatectomy liver failure (PHLF), carries high mortality. However, the key mechanisms underlying irreversible remnant liver injury and cell death remain poorly understood, particularly regarding the contribution of lipid metabolism. This study investigates the contribution of lipid metabolism remodeling to post-hepatectomy hepatocyte injury and identifies potential therapeutic targets.
Methods: We integrated murine graded PHx models, human liver tissues from associating liver partition and portal vein ligation for staged hepatectomy (ALPPS), multi-omics, and machine learning to identify key regulatory genes. Underlying mechanisms were validated via in vitro and in vivo genetic manipulation, alongside pharmacological modulation.
Results: We revealed that aberrant glycerophospholipid metabolism is the primary driver of endoplasmic reticulum stress (ERS) -mediated pyroptosis in the remnant liver. Multi-omics analysis combined with machine learning identified death receptor 5 (DR5) as a critical regulator. Mechanistically, DR5 physically impeded the nuclear translocation of the Farnesoid X Receptor (FXR), thereby repressing the transcription of Chpt1 (Cholinephosphotransferase 1). The consequent deficiency in phosphatidylcholine (PC) compromised ER membrane integrity, exacerbating the Unfolded Protein Response and triggering lethal pyroptosis. Restoring the DR5-FXR-CHPT1 axis via AAV-mediated DR5 knockdown, FXR agonists, or exogenous PC supplementation significantly alleviated post-hepatectomy liver injury.
Conclusions: Our study uncovers a non-canonical metabolic function of DR5 that disrupts ER membrane homeostasis via the FXR-CHPT1 axis, leading to fatal hepatocyte pyroptosis. Targeting this active metabolic reprogramming offers a promising therapeutic strategy to prevent PHLF and SFSS after major PHx.
关于派真
作为一家专注于AAV 技术十余年，深耕基因治疗领域的CRO&CDMO，派真生物可提供从载体设计、构建到 AAV、慢病毒和 mRNA 服务的一站式解决方案。凭借深厚的技术实力、卓越的运营管理和高标准的服务交付，我们为全球客户提供一站式CMC解决方案，包括从早期概念验证、成药性评估到IIT、IND及BLA的各个阶段。
凭借我们独立知识产权的π-alphaTM 293 细胞AAV高产技术平台，我们能将AAV产量提高多至10倍，每批次产量可达1×10¹⁷vg，以满足多样化的商业化和临床项目需求。此外，我们定制化的mRNA和脂质纳米颗粒（LNP）产品及服务覆盖药物和疫苗开发的各个阶段，从研发到符合GMP的生产，提供端到端的一站式解决方案。
